Evaluation of Two Cell-based Assays for Diagnosing MOG-IgG Associated Disorders

计划入组 240 人 · 首次发布于 2024 年 10 月 1 日

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)

计划入组 113 人 · 首次发布于 2021 年 9 月 30 日

Azathioprine in MOGAD

计划入组 126 人 · 首次发布于 2022 年 4 月 27 日

MOG-4

MOG-1

MOG-2

MVG Industries SAS

Belgium

EPITECH MAG LTD

Israel

Fog Pharmaceuticals, Inc.

United States

Phase 3 MOGwAI Trial Investigates Azathioprine for First-Line MOGAD Treatment

Regulatory T Cell Therapy Unexpectedly Promotes Pathogenic Th17 Cell Generation Through IL-2 Suppression

BrainXell's BXT-110 Shows Promising Preclinical Results for Parkinson's Disease Cell Therapy